Everything drug pricing and policy, every day
And I need your vote in a very, very important poll
And a not-very-insightful launch price paper has a not-very-transparent funding source
And companies with new meds are (again) getting shy about revealing prices at approval
Plus 84 pages on what the Democrats will do on healthcare if they retake the House
Plus more data on the link -- or lack thereof -- between 340B revenue and charity care
And a deep dive on 340B hospital financial assistance policies
And Chris Klomp’s ducked MFN and TrumpRx questions from Senators; his nomination advances anyway
And pressure on Europe -- especially Germany -- to raise drug prices intensifies